Dr. Tanju YILDÖN & Tıp Bilim Eğitimi

Emicizumab ’ın hedef aldığı molekül; Faktör IXa ve X. Kullanıldığı patoloji; hemofili A

Novel Insights and New Developments Regarding Coagulation Revealed by  Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific  Antibody, Emicizumab | Arteriosclerosis, Thrombosis, and Vascular Biology